Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients

BACKGROUND AND AIM: Tenofovir disoproxil fumarate (TDF) has been efficacious in treating chronic hepatitis B (CHB), but long‐term use is accompanied by a decline in renal function and bone mineral density (BMD). Tenofovir alefanamide (TAF) is a prodrug of tenofovir, with similar efficacy in CHB but...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Brian T, Chang, Mimi, Lim, Carolina, Bae, Ho S, Fong, Tse‐Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857293/
https://www.ncbi.nlm.nih.gov/pubmed/33553665
http://dx.doi.org/10.1002/jgh3.12481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857293/
https://www.ncbi.nlm.nih.gov/pubmed/33553665
http://dx.doi.org/10.1002/jgh3.12481

Ejemplares similares